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almost 12%. Approximately ﬁve patients need to be
placed on treatment to avoid one year of full-time care,
resulting in incremental savings in the majority of 
countries.
CONCLUSIONS: Delaying the time to full-time care is
expected to produce savings in the majority of health care
systems. Galantamine was considered to be an economi-
cally dominant strategy compared to no treatment in
most health care systems.
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“Revolving door” schizophrenia, characterized by fre-
quent hospitalizations, is very costly to the health care
system. Standard treatment is depot injection of typical
antipsychotics. Atypical antipsychotics in depot form are
expected to be more efﬁcacious that typical depots yet
will cost much more.
OBJECTIVES: We estimated the total healthcare costs,
from a third party payer perspective, of treating 
revolving door schizophrenia with depot formulations of
risperidone and olanzapine as compared to the status
quo, haloperidol decanoate.
METHODS: Because depot forms of risperidone and
olanzapine are in development, a modeling approach 
was used. The Markov model depicted events (medica-
tion adherence and relapse, deﬁned as hospitalization and
switch to clozapine) leading to three Markov states: in
community on depot, hospitalized, and in community on
clozapine. Clinical probabilities were derived from ran-
domized, controlled trials of comparable oral drugs. Unit
costs were obtained from an administrative database and
provincial fee schedule and formulary. Product costs for
the atypical depots were based on their respective oral
costs. Monte Carlo simulation of 10,000 patients was
done with a cycle length of one month and time horizon
of 5 years. Probabilistic sensitivity analyses were done 
on all data estimates using Monte Carlo simulation.
Threshold analyses were also done on the drug costs.
RESULTS: Total 5-year base case costs (SD) for haloperi-
dol, risperidone and olanzapine alternatives were (Can.)
$17,865 (10,867), $15,146 (9797) and $22,362 (6509)
respectively. Mean hospitalizations per patient were
lowest for olanzapine (0.68) and highest for haloperidol
(1.07). Total costs were sensitive only to the risperidone
and olanzapine product costs with thresholds of $160
and $177 per month, respectively.
CONCLUSION: Compared with haloperidol decanoate,
total healthcare costs for treating “revolving door” schiz-
ophrenia were greater for olanzapine depot and less for
risperidone depot. For olanzapine hospitalization savings
were insufﬁcient to offset its much higher product cost.
The relative impact of atypical depots on total healthcare
costs will depend strongly on their price.
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The new atypical antipsychotics, although more expen-
sive than traditional agents, may reduce the ﬁnancial
burden posed by schizophrenic illness.
OBJECTIVE: The objective of this study was to compare
risperidone versus olanzapine on their impact on the
mental health care costs of schizophrenia in a “real-
world” setting.
METHODS: This was a retrospective, comparative study
based on claims data obtained from two large health care
plans during 1996 and 1997. The primary variable ana-
lyzed was net patient mental health care cost per member
per month (PMPM), deﬁned as total mental health care
cost excluding antipsychotic drug cost during treatment
episodes with risperidone or olanzapine. The individual
components of net mental health care costs were also 
analyzed. Between-group comparisons (for patients who
received one or the other of the antipsychotics) were per-
formed, controlling for differences in patient characteris-
tics. Data was obtained from medical and prescription
drug claims of individuals with schizophrenic disorders.
Regression models combining risperidone and olanzapine
treatment episodes were estimated to determine their
effects on mental health resource use.
RESULTS: A total of 129 risperidone (128 individuals)
and 273 olanzapine (271 individuals) treatment episodes
for schizophrenic disorders fell within the study period.
Most components of mental health care costs were lower
with risperidone than with olanzapine. Depending on the
method of estimation, between-group regression models
showed that risperidone reduced net mental health care
cost PMPM by 36% p < 0.01) or 53% (p < 0.01) and
total mental health care cost PMPM (inclusive of antipsy-
chotic drug cost) by 32% (p < 0.01) or 44% (p < 0.01)
compared with olanzapine. The major difference between
risperidone and olanzapine users was in inpatient costs,
which were 58% or 68% ($168 or $266) lower PMPM
with risperidone, depending on the method of estimation.
CONCLUSION: Relative to olanzapine, risperidone is
associated with reduced mental health costs for schizo-
phrenia patients in managed care populations.
